News

We send the latest information from SMC Laboratories.

2023.12.20

NEWS RELEASE

Fibrosis is involved in many diseases and disease-related deaths

Today's topic is Fibrosis. We would like to discuss with you the importance of therapeutic treatments tha…

READ MORE

2023.12.13

PRODUCTS AND SERVICE

Introduction of bleomycin-induced SSc-ILD model

Today, we would like to introduce a more clinically correlative model in which skin and lung fibrosis develop …

READ MORE

2023.12.08

PRODUCTS AND SERVICE

STAM™ mice study: demonstration of MSCs-based cell therapy study for the NASH treatment

We introduce an example of a drug evaluation study on the efficacy of cell therapy in the treatment of NASH us…

READ MORE

2023.11.30

PUBLICATION

Study published in Cells. on the effects of ameliorating epigenetic modifications by ATP1A1 signalosome inhibition in the liver cancer of STAM™ mice

SMC is proud to announce that Marshall University (WV) has published the results of their study using our pre-…

READ MORE

2023.11.15

NEWS RELEASE

World COPD Day 2023 | “Breathing is Life – Act Earlier”

November 15th is World COPD Day, so why not learn more about COPD?   What is World COPD Day? World COPD D…

READ MORE

2023.11.09

PUBLICATION

【New Preclinical Data】 The effects of Il-18 inhibitor on cholangitis and liver fibtrosis in DDC-induced primary sclerosing cholangitis (PSC) model mice

We are pleased to announce that our client AprilBio Co., Ltd. (KOR) published the results of preclinical studi…

READ MORE

2023.11.02

PUBLICATION

SMC will present study at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting

We will be presenting our study on STAM™ mice at the American Association for the Study of Liver Disease…

READ MORE

2023.10.20

EVENT

SMC will be exhibiting at The 31st Japan Digestive Disease Week (JDDW 2023)

We are pleased to announce that SMC Laboratories will be exhibiting at The 31st Japan Digestive Disease Week (…

READ MORE

2023.10.05

NEWS RELEASE

Exciting News! Galectin Therapeutics announces positive outcome of the fourth data from its seamless adaptive Phase 2b/3 trial of Belapectin (GR-MD-02) in liver cirrhosis due to NASH/MASH

Galectin Therapeutics (GA) announced on 3rd October, 2023, positive outcome of the fourth d ata and Safety Mon…

READ MORE

2023.09.28

PUBLICATION

Study published in Biomed Pharmacother. on the effects of GRP119 agonist in the treatment of NASH in STAM™ mice

SMC is proud to announce that Dong-A ST Co., Ltd. (KOR) has published the results of their study using our pre…

READ MORE

Page 3 of 19First12345Last